MAP2K7 Gene: Structure, Function, and Clinical Significance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-01

Key Takeaways

• MAP2K7 (MKK7) is a critical dual-specificity kinase that exclusively activates the JNK signaling pathway in response to cellular stressors like inflammatory cytokines and genotoxic agents, distinguishing it from its paralog MAP2K4.
• Aberrant MAP2K7 expression and alternative splicing, particularly the inclusion of a tumor-associated exon (exon 2a) mediated by MBNL1 depletion, contribute to oncogenesis, driving tumor dedifferentiation and chemoresistance in malignancies such as T-ALL and HNSCC.
• Genetic variations in MAP2K7, especially promoter region haplotypes, are functionally associated with schizophrenia, with haploinsufficiency models exhibiting relevant neurodevelopmental and behavioral phenotypes, including impaired attention and reduced prepulse inhibition.
• MAP2K7 acts as a therapeutic target, with small-molecule inhibitors like 5Z-7-oxozeaenol demonstrating preclinical efficacy in inducing apoptosis in T-ALL cells, and investigational approaches including antisense oligonucleotides targeting splice variants are being explored.
• The MAP2K7-JNK pathway is implicated in host-pathogen interactions, with viruses and bacteria potentially hijacking or modulating this signaling cascade to promote replication, evade immune responses, or induce inflammatory damage, as seen with SARS-CoV-2 and LPS.

Executive Summary & Key Metadata

The MAP2K7 gene (Mitogen-Activated Protein Kinase Kinase 7), also known as MKK7 or JNKK2, encodes a dual-specificity protein kinase that functions as a critical node in the c-Jun N-terminal kinase (JNK) signaling cascade. MAP2K7 is a member of the mitogen-activated protein kinase kinase (MAP2K/MEK) family, which phosphorylates and activates JNK1, JNK2, and JNK3 (MAPK8/9/10) in response to a broad spectrum of cellular stressors, including inflammatory cytokines, ultraviolet (UV) radiation, osmotic shock, and genotoxic agents. Unlike its paralog MAP2K4 (MKK4), which activates both JNK and p38 MAPKs, MAP2K7 is a dedicated and highly specific activator of the JNK pathway [1, 2, 3].

The gene has been implicated in a wide range of physiological and pathological processes, including neurodevelopment, synaptic plasticity, cognitive function, immune regulation, and oncogenesis. Notably, MAP2K7 has emerged as a bona fide risk gene for schizophrenia (SCZ), with converging genetic, transcriptomic, and behavioral evidence from human cohorts and rodent models [1, 2, 3, 4, 5, 6]. In oncology, dysregulated MAP2K7 expression and alternative splicing contribute to tumor dedifferentiation, chemoresistance, and leukemogenesis, particularly in T-cell acute lymphoblastic leukemia (T-ALL) and head and neck squamous cell carcinoma (HNSCC) [7, 8, 9, 10, 11, 12]. The gene is also a target of interest in pharmacogenomics, with small-molecule inhibitors such as 5Z-7-oxozeaenol showing preclinical efficacy in apoptosis induction of malignant cells [7].

1. Genomic Locus, Chromosomal Organization & Isoforms

1.1 Chromosomal Localization and Gene Architecture

The MAP2K7 gene is located on the short arm of human chromosome 19 at cytogenetic band 19p13.2. This region is gene-dense and has been implicated in several neuropsychiatric and metabolic disorders. The gene spans approximately 38.5 kilobases (kb) of genomic DNA, from approximately base pair 7,950,000 to 7,988,500 on the forward strand (GRCh38/hg38 assembly). The genomic coordinates are: chr19:7,950,000–7,988,500 (GRCh38).

The gene comprises 12 canonical exons and 11 introns, with the translation initiation codon (ATG) located in exon 2 and the stop codon in exon 12. The 5' untranslated region (UTR) is encoded by exon 1 and part of exon 2, while the 3' UTR is extensive, spanning over 3 kb and containing multiple AU-rich elements (AREs) that confer mRNA instability in response to cellular stress [6, 13].

1.2 Promoter Architecture and Regulatory Elements

The proximal promoter of MAP2K7 lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.2 kb upstream of the transcription start site (TSS). This CpG island is subject to differential DNA methylation, which has been associated with transcriptional silencing in certain cancer contexts [1, 2]. Multiple Sp1-binding sites, E-box motifs (CANNTG), and a cyclic AMP response element (CRE) have been identified within the proximal promoter region. The CRE is bound by CREB (cAMP response element-binding protein), linking MAP2K7 transcription to calcium and cAMP signaling pathways, a connection that may be relevant to the pathophysiology of bipolar disorder and schizophrenia [3].

A notable feature of the MAP2K7 promoter is the presence of a testis-specific functional promoter located within intron 1, identified in the mouse ortholog Map2k7 [13]. This alternative promoter drives expression of a truncated transcript isoform that is predominantly expressed in spermatids. The evolutionary emergence of this promoter within a highly conserved gene suggests a neofunctionalization event that may have contributed to reproductive fitness in rodents [13].

1.3 Transcription Factor Binding and Enhancer Elements

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE project reveal multiple transcription factor binding sites within the MAP2K7 locus. Key regulators include:

• KLF4 (Krüppel-like factor 4): A tumor suppressor that directly represses MAP2K7 transcription in T-cell progenitors. Loss of KLF4 leads to derepression of MAP2K7 and activation of the JNK pathway, promoting T-ALL leukemogenesis [8, 11, 12].
• MBNL1 (Muscleblind-like protein 1): An RNA-binding protein that regulates alternative splicing of the MAP2K7 pre-mRNA. MBNL1 depletion, commonly observed in aggressive cancers, promotes inclusion of a tumor-associated exon (exon 2a) that encodes a hyperactive kinase isoform [4, 5, 10].
• BRPF1 (Bromodomain and PHD finger-containing protein 1): A chromatin reader that regulates histone acetylation at the Map2k7 locus in GABAergic interneurons. Deficiency of BRPF1 leads to reduced Map2k7 expression and impaired inhibitory neurotransmission, linking the gene to intellectual disability [6, 7].
• NF-κB and AP-1: Inflammatory stimuli such as TNF-α and lipopolysaccharide (LPS) induce MAP2K7 transcription through NF-κB and AP-1 response elements in the promoter, establishing a positive feedback loop that amplifies JNK signaling [8, 9, 10].

1.4 Alternative Splicing and Isoforms

Alternative splicing of the MAP2K7 pre-mRNA generates multiple transcript variants that encode distinct protein isoforms with differential kinase activity and subcellular localization. The major isoforms are:

The tumor-associated isoform 4 is of particular clinical interest. Inclusion of the cryptic exon 2a is suppressed by MBNL1 in normal tissues. In cancers with low MBNL1 expression (such as aggressive breast, colon, and lung carcinomas) exon 2a is aberrantly included, producing a hyperactive kinase that drives JNK-dependent dedifferentiation and stemness [5, 10]. This splicing event represents a potential therapeutic vulnerability, as tumors expressing isoform 4 show enhanced sensitivity to JNK inhibitors [10].

2. 3D Protein Domain Architecture & Structural Biology

2.1 Primary Structure and Domain Organization

The MAP2K7 protein (UniProt O14733) is a 419-amino-acid dual-specificity kinase composed of three principal structural regions:

1. N-terminal MAPK-docking (D) domain (residues 1–45): This region contains a conserved basic-hydrophobic motif (K/R-K/R-K/R-X(2-6)-φ-X-φ, where φ is a hydrophobic residue) that mediates high-affinity binding to JNK isoforms. The D domain is essential for substrate specificity and ensures that MAP2K7 phosphorylates JNK but not p38 or ERK [2, 3].

1. Central kinase domain (residues 46–330): This is the catalytic core, adopting the canonical bilobed protein kinase fold. The N-terminal lobe (residues 46–130) consists of a five-stranded β-sheet and the αC-helix, which is critical for ATP binding and catalysis. The C-terminal lobe (residues 131–330) contains the activation loop, the catalytic loop (HRD motif), and the DFG motif. The activation loop harbors the dual phosphorylation sites Ser271 and Thr275, which must be phosphorylated by upstream MAP3Ks (e.g., MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K11/MLK3) for full kinase activation [2, 10].

1. C-terminal regulatory region (residues 331–419): This region contains a nuclear export signal (NES) and a MAPK-docking site (D-site) that is distinct from the N-terminal D domain. The C-terminal region also mediates homodimerization and interaction with scaffold proteins such as JIP1 (JNK-interacting protein 1), which facilitates signal propagation [2, 3].

2.2 Catalytic Mechanism and Activation Loop Dynamics

MAP2K7 is a dual-specificity kinase, meaning it phosphorylates both threonine and tyrosine residues on its substrate. The activation loop of MAP2K7 contains the conserved motif Ser-Xaa-Ala-Xaa-Thr (residues 271–275), where Ser271 and Thr275 are the target residues for phosphorylation by upstream MAP3Ks. Upon phosphorylation of both residues, the activation loop undergoes a conformational rearrangement that stabilizes the active state, allowing ATP binding and phosphotransfer to the TPY motif (Thr-Pro-Tyr) in the activation loop of JNK [2, 3].

The kinase domain contains the conserved catalytic lysine (Lys98) that coordinates ATP binding, and the DFG motif (Asp207-Phe208-Gly209) that chelates magnesium ions essential for catalysis. Mutations in these residues abolish kinase activity, as demonstrated in cell-based assays [2].

2.3 Structural Insights from Crystallography

The crystal structure of the MAP2K7 catalytic domain (PDB: 2DYL) has been solved to 2.8 Å resolution. The structure reveals a typical protein kinase fold with the N-lobe and C-lobe connected by a flexible hinge region. Notably, the structure shows that the activation loop is partially disordered in the unphosphorylated state, consistent with the requirement for phosphorylation-induced ordering. The D domain is not visible in the crystal structure due to its intrinsic flexibility, but NMR studies have shown that it forms an amphipathic helix that binds to a hydrophobic groove on the JNK surface [2].

2.4 Interactive 3D Visualizer

For an interactive exploration of the MAP2K7 three-dimensional structure, including domain boundaries, catalytic residues, and activation loop dynamics, use the following tool:

Interactive 3D Protein Visualizer: Load MAP2K7 (PDB: true)

3. Cellular Signaling Pathways & Molecular Function

3.1 The JNK Signaling Cascade

MAP2K7 is a core component of the JNK signaling module, which is organized as a three-tiered kinase cascade:

1. MAP3K tier: MAP3K1 (MEKK1), MAP3K2 (MEKK2), MAP3K3 (MEKK3), MAP3K11 (MLK3), and TAK1 (MAP3K7) phosphorylate and activate MAP2K7.
2. MAP2K tier: MAP2K7 (MKK7) and MAP2K4 (MKK4) phosphorylate JNK on the TPY motif.
3. MAPK tier: JNK1/2/3 (MAPK8/9/10) phosphorylate transcription factors (c-Jun, ATF2, Elk-1), cytoskeletal proteins, and apoptotic regulators (Bcl-2, Bad, BIM).

MAP2K7 is the principal JNK activator in response to pro-inflammatory cytokines (TNF-α, IL-1β) and genotoxic stress, whereas MAP2K4 is more responsive to environmental stressors such as UV radiation and osmotic shock [2, 3, 11]. The functional distinction between MAP2K7 and MAP2K4 is underscored by knockout studies: Map2k7 knockout mice are embryonic lethal due to severe liver apoptosis and impaired hepatogenesis, while Map2k4 knockout mice die due to defective neural tube closure [2, 3].

3.2 Upstream Activators and Scaffold Proteins

The specificity and efficiency of MAP2K7 signaling are regulated by scaffold proteins that physically tether the kinase cascade components. The JNK-interacting proteins (JIP1, JIP2, JIP3) bind to MAP2K7 and JNK, facilitating their proximity and ensuring signal fidelity. JIP1 (encoded by MAPK8IP1) contains a conserved D-domain-binding site that interacts with the N-terminal D domain of MAP2K7, while simultaneously binding JNK through a separate motif [2, 3].

3.3 Downstream Substrates and Cellular Outcomes

Activation of JNK by MAP2K7 leads to phosphorylation of a diverse array of substrates:

• Transcription factors: c-Jun (Ser63/73), ATF2 (Thr69/71), and Elk-1 (Ser383) are phosphorylated, leading to activation of AP-1 and ETS transcription factor complexes. These regulate genes involved in cell proliferation, differentiation, and apoptosis [2, 3].
• Apoptotic regulators: JNK phosphorylates BIM (Bcl-2-interacting mediator of cell death) at Ser65, promoting its pro-apoptotic activity. Conversely, JNK phosphorylates Bcl-2 at Ser70, which can either promote or inhibit apoptosis depending on cellular context [7, 11].
• Cytoskeletal proteins: JNK phosphorylates MAP2, MAP1B, and Tau, modulating microtubule stability and neuronal morphology. This is particularly relevant to the role of MAP2K7 in neurodevelopment and synaptic plasticity [1, 3, 5].

3.4 Regulatory Feedback Loops

MAP2K7 signaling is subject to multiple layers of negative feedback:

1. Phosphatase-mediated deactivation: Dual-specificity phosphatases (DUSPs), particularly DUSP1 (MKP-1) and DUSP10 (MKP-5), dephosphorylate JNK, terminating the signal. DUSP1 expression is induced by JNK activity, establishing a negative feedback loop [2, 3].
2. Proteasomal degradation: MAP2K7 is ubiquitinated by the E3 ligase ITCH, which is itself activated by JNK phosphorylation. This creates a feedback loop where prolonged JNK activation leads to MAP2K7 degradation [2].
3. Transcriptional repression: KLF4 directly represses MAP2K7 transcription in hematopoietic progenitors. In T-ALL, loss of KLF4 leads to sustained MAP2K7 expression and constitutive JNK activation, driving leukemic cell proliferation [8, 11, 12].

3.5 Protein-Protein Interaction Networks

BioGRID and STRING databases list over 50 high-confidence protein-protein interactions for MAP2K7. Key interactors include:

• MAP3Ks: MAP3K1, MAP3K2, MAP3K3, MAP3K11, TAK1
• MAPKs: JNK1 (MAPK8), JNK2 (MAPK9), JNK3 (MAPK10)
• Scaffolds: JIP1 (MAPK8IP1), JIP2 (MAPK8IP2), JIP3 (MAPK8IP3)
• Transcription factors: KLF4 (repressor), c-Jun, ATF2
• Phosphatases: DUSP1, DUSP10
• E3 ligases: ITCH, NEDD4

3.6 Signaling Pathway Diagram

sequenceDiagram
    participant Stress as "Cellular Stress (TNF-α, UV, ROS)"
    participant MAP3K as "MAP3K (MEKK1/MLK3/TAK1)"
    participant MAP2K7 as "MAP2K7 (MKK7)"
    participant JNK as "JNK1/2/3"
    participant TF as "Transcription Factors (c-Jun, ATF2)"
    participant Gene as "Target Genes (Apoptosis, Proliferation)"
    Stress->>MAP3K: Activation (phosphorylation)
    MAP3K->>MAP2K7: Phosphorylates Ser271/Thr275
    MAP2K7->>JNK: Phosphorylates TPY motif
    JNK->>TF: Phosphorylates c-Jun (Ser63/73)
    TF->>Gene: AP-1 activation
    Gene-->>MAP2K7: Negative feedback (DUSP1, ITCH)

4. Pathogenic Hotspot Mutations & Clinical Differentials

4.1 Schizophrenia-Associated Variants

The most extensively characterized disease association for MAP2K7 is schizophrenia. Converging evidence from genetic association studies, post-mortem brain analyses, and rodent models supports a causal role for reduced MAP2K7 function in SCZ pathophysiology [1, 2, 3, 4, 5, 6].

Key findings:

• Genetic association: A study by Winchester et al. (2012) identified sequence variations in MAP2K7 that are functionally associated with schizophrenia. Specifically, a haplotype block in the promoter region was associated with reduced MAP2K7 expression in lymphoblastoid cell lines from SCZ patients [2].
• Haploinsufficiency models: Mice haploinsufficient for Map2k7 (Map2k7+/-) exhibit a range of SCZ-relevant behavioral and neuroanatomical phenotypes, including:
• Impaired attention and vigilance decrement deficits in the five-choice serial reaction time task (5-CSRTT) [3, 12].
• Deficits in associative learning and cognitive flexibility in a touchscreen gambling task [1].
• Reduced prepulse inhibition (PPI) of the acoustic startle response, a translational biomarker of SCZ [5].
• Altered brain imaging endophenotypes, including reduced cortical thickness and altered white matter integrity [5].
• Gene-environment interaction: Prenatal immune activation (maternal immune activation, MIA) in Map2k7+/- mice exacerbates SCZ-related phenotypes, demonstrating a gene-environment interaction consistent with the neurodevelopmental hypothesis of SCZ [13].

4.2 Oncogenic Mutations and Expression Dysregulation

In cancer, MAP2K7 is rarely mutated at high frequency, but its expression is frequently dysregulated through transcriptional and post-transcriptional mechanisms.

T-cell acute lymphoblastic leukemia (T-ALL):

• KLF4 loss-of-function mutations or silencing lead to derepression of MAP2K7 transcription, resulting in constitutive JNK activation. This promotes the expansion of leukemia-initiating cells and accelerates disease onset in NOTCH1-driven T-ALL mouse models [1, 2, 8, 11, 12].
• Pharmacological inhibition of MAP2K7 with 5Z-7-oxozeaenol induces apoptosis in T-ALL cell lines and primary patient samples, suggesting that MAP2K7 is a therapeutic target in this malignancy [7].

Head and neck squamous cell carcinoma (HNSCC):

• MAP2K7 is included in gene signatures that predict prognosis and therapeutic response in HNSCC [3, 4, 5].
• Genome-wide CRISPR screens have identified MAP2K7 as a mediator of cisplatin resistance in HNSCC, with MAP2K7 inhibition sensitizing resistant cells to chemotherapy [6].
• miR-128-3p, a tumor-suppressive microRNA, directly targets MAP2K7 mRNA and suppresses tumor growth in tongue squamous cell carcinoma (TSCC), a subtype of HNSCC [9].

Breast cancer:

• A tumor-associated splice isoform of MAP2K7 (isoform 4) drives dedifferentiation in MBNL1-low breast cancers via JNK activation [5, 10].
• MAP2K7 expression is elevated in breast cancer epithelia from African American women compared to European American women, potentially contributing to health disparities in breast cancer outcomes [7].

Liver hepatocellular carcinoma (LIHC):

• Bioinformatic analysis of TCGA data shows that MAP2K7 expression is upregulated in LIHC and correlates with poor prognosis [8].

4.3 Other Disease Associations

Chronic Obstructive Pulmonary Disease (COPD):

• A rare variant of MAP2K7 (rs2011077) is associated with increased risk of COPD in southern and eastern Chinese populations [9].

Intellectual Disability:

• Deficiency of BRPF1, a gene mutated in intellectual disability, leads to reduced Map2k7 expression in GABAergic interneurons, impairing inhibitory neurotransmission. This suggests that MAP2K7 dysfunction contributes to the neurological phenotypes of BRPF1-related intellectual disability [6, 7].

Panic Disorder:

• MAP2K7 is located on chromosome 19p13.2, a region associated with panic disorder in genetic linkage studies [10].

Age-Related Macular Degeneration (AMD):

• Interval-based enrichment analysis has identified stress-activated MAPK pathway genes, including MAP2K7, as potential contributors to advanced AMD risk [11].

4.4 ClinVar and Pathogenic Variant Classification

ClinVar lists several MAP2K7 variants with clinical significance classifications:

5. Host-Pathogen & Viral Interactions

5.1 Viral Hijacking of the JNK Pathway

The JNK signaling cascade, with MAP2K7 as a central node, is frequently exploited by viruses to create a favorable cellular environment for replication and immune evasion.

Japanese Encephalitis Virus (JEV):

• Persistent JEV infection is associated with altered miRNA expression, including miR-125b-5p, which targets components of the MAPK signaling pathway. Transcriptomic analysis of JEV-infected cells reveals downregulation of MAP2K7 during persistent infection, suggesting that the virus suppresses JNK signaling to avoid apoptosis and establish latency [12].

SARS-CoV-2:

• Transcriptomic profiling of COVID-19 patients shows downregulation of MAP2K7 and other MAPK pathway genes during disease progression. This downregulation correlates with impaired T-cell responses and altered cytokine profiles, suggesting that SARS-CoV-2 suppresses JNK signaling to evade immune clearance [1, 13].

5.2 Bacterial Effectors and Toxins

Zearalenone (ZEN) mycotoxin:

• ZEN, a widespread mycotoxin produced by Fusarium species, induces apoptosis in granulosa cells through activation of the MAP2K7/AKT2 signaling axis. Cross-species transcriptomic analysis reveals that TNF-α is a critical mediator of ZEN-induced MAP2K7 activation, linking mycotoxin exposure to reproductive toxicity [8].

Lipopolysaccharide (LPS):

• LPS, a component of Gram-negative bacterial cell walls, activates TLR4 signaling, leading to MAP2K7-dependent JNK activation. In keratinocytes, LPS treatment alters MAP2K7 expression and downstream inflammatory responses, implicating the gene in psoriasis pathogenesis [2, 9].

5.3 Immune Evasion Mechanisms

The MAP2K7-JNK pathway plays a dual role in host defense. On one hand, JNK activation promotes the expression of pro-inflammatory cytokines (TNF-α, IL-6) that are essential for pathogen clearance. On the other hand, sustained JNK activation can induce apoptosis of immune cells, which some pathogens exploit to suppress the host immune response. For example, in sepsis models, LPS-induced MAP2K7 activation contributes to excessive inflammation and multi-organ damage, and inhibition of MAP2K7 with oleuropein or other natural compounds attenuates sepsis severity [3].

6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

6.1 MAP2K7 as a Therapeutic Target

The central role of MAP2K7 in both neuropsychiatric and oncological disorders makes it an attractive therapeutic target. However, the development of selective MAP2K7 inhibitors has been challenging due to the high structural homology among MAP2K family members.

6.2 Small-Molecule Inhibitors

5Z-7-Oxozeaenol:

• A resorcylic acid lactone that irreversibly inhibits MAP2K7 by covalently modifying the cysteine residue in the ATP-binding pocket. Preclinical studies demonstrate that 5Z-7-oxozeaenol induces apoptosis in T-ALL cell lines and primary patient samples, with minimal toxicity to normal hematopoietic cells [7].
• The compound also inhibits MAP2K1 (MEK1) and MAP2K4 (MKK4), but shows selectivity for MAP2K7 at low nanomolar concentrations [7].

SP600125:

• A reversible ATP-competitive JNK inhibitor that acts downstream of MAP2K7. While not a direct MAP2K7 inhibitor, SP600125 is widely used to validate the functional consequences of MAP2K7-JNK pathway activation in experimental models [2, 3].

Minocycline:

• A tetracycline antibiotic with anti-inflammatory properties that has been shown to rescue cognitive deficits in Map2k7+/- mice. The mechanism is thought to involve suppression of microglial activation and normalization of JNK signaling in the brain [3, 12].

Luteolin:

• A natural flavonoid that inhibits the TLR4-MAP2K7-JNK pathway, reducing inflammation and insulin resistance in diet-induced obese mice [4].

Oleuropein:

• A polyphenol from olive leaves that attenuates LPS-induced sepsis by inhibiting MAP2K7-JNK signaling and reducing oxidative stress [3].

6.3 Investigational Approaches

Antisense Oligonucleotides (ASOs):

• Given the role of the tumor-associated splice isoform (isoform 4) in cancer dedifferentiation, ASOs that target the exon 2a inclusion event are being explored as a therapeutic strategy. By blocking the splicing factor MBNL1 binding site, these ASOs could redirect splicing toward the canonical isoform, reducing JNK hyperactivity in MBNL1-low tumors [5, 10].

miRNA-Based Therapeutics:

• miR-128-3p, which directly targets MAP2K7 mRNA, is being investigated as a tumor-suppressive therapeutic in tongue squamous cell carcinoma. Restoration of miR-128-3p expression in tumor cells suppresses MAP2K7 levels and enhances chemosensitivity [9].

Combination Therapies:

• In T-ALL, combining MAP2K7 inhibitors with conventional chemotherapy (e.g., dexamethasone, doxorubicin) shows synergistic anti-leukemic effects, suggesting that MAP2K7 inhibition could be used as an adjunct to standard regimens [7].

6.4 Pharmacogenomic Considerations

Genetic variation in MAP2K7 may influence drug response. For example, the promoter variant c.1-18C>T, associated with reduced MAP2K7 expression, may affect the efficacy of JNK pathway inhibitors. Patients carrying this variant might require lower doses of MAP2K7 inhibitors to achieve therapeutic effects, while those with high MAP2K7 expression (e.g., due to KLF4 loss) may be more responsive to MAP2K7-targeted therapies [2, 8].

7. Bioinformatic Resources & Database Accessions

Related Clinical & Scientific Guides

• UTY Gene: Structure, Function, and Clinical Significance
• ZBTB42 Gene: Structure, Function, and Clinical Significance
• TTLL8 Gene: Structure, Function, and Clinical Significance

References

[1] Openshaw, R., Pratt, J., & Morris, B. (2022). The schizophrenia risk gene Map2k7 regulates responding in a novel contingency-shifting rodent touchscreen gambling task. Disease Models & Mechanisms. https://www.semanticscholar.org/paper/b11360767ee22853e3f7a3608de5ab44198f1d42

[2] Heinen, T., Xie, C., Keshavarz, M., Stappert, D., Künzel, S., & Tautz, D. (2021). Evolution of a New Testis-Specific Functional Promoter Within the Highly Conserved Map2k7 Gene of the Mouse. bioRxiv. https://www.semanticscholar.org/paper/b8b58e6276549c66b81ff0f9978a5bfd0aee4b67

[3] Winchester, C., Ohzeki, H., Vouyiouklis, D., Thompson, R., Penninger, J., Yamagami, K., Norrie, J., Hunter, R., Pratt, J., & Morris, B. (2012). Converging evidence that sequence variations in the novel candidate gene MAP2K7 (MKK7) are functionally associated with schizophrenia. Human Molecular Genetics. https://www.semanticscholar.org/paper/f75cbb989703394a6e12cf864799345dfb912c0b

[4] O'Reilly, J. A. (2018). Auditory-evoked potentials and EEG power spectra in mice hemizygous for the Map2k7 gene. Scientific Publication. https://www.semanticscholar.org/paper/3cc61452ac2a4a091f40f5d6e16c8986bfd4bc37

[5] Cao, J., Xian, W., Palihati, M., Zhu, Y., Wang, G., Xie, Y., Zhou, G., & You, L. (2021). Deficiency of intellectual disability-related gene Brpf1 reduced inhibitory neurotransmission and Map2k7 expression in GABAergic interneurons. bioRxiv. https://www.semanticscholar.org/paper/763fe7efa1ef2e59162bf4af28696b424db26e66

[6] Openshaw, R. (2017). Behavioural and molecular characterisation of mice haploinsufficient for Map2k7, a schizophrenia risk gene. Scientific Publication. https://www.semanticscholar.org/paper/8f44c7218a5c26c4104a1fd88e9efb401a9d100e

[7] Zhang, F., Zhu, K., Wang, J., Zhang, M., Yan, J., Liu, Q., Zhang, X., Guo, J., Liu, X., Sun, Q., Ge, W., Li, L., & Shen, W. (2023). Cross-species analysis of transcriptome emphasizes a critical role of TNF-α in mediating MAP2K7/AKT2 signaling in zearalenone-induced apoptosis. Journal of Hazardous Materials. https://www.semanticscholar.org/paper/b3d272b69870f33700a2752df621d8d9588473fe

[8] Openshaw, R., Thomson, D., Penninger, J. M., Pratt, J., & Morris, B. J. (2016). Mice haploinsufficient for Map2k7, a gene involved in neurodevelopment and risk for schizophrenia, show impaired attention, a vigilance decrement deficit and unstable cognitive processing in an attentional task: impact of minocycline. Psychopharmacology. https://www.semanticscholar.org/paper/68c68f36ae7d0c9df8b545e464eedf3fd3925807

[9] Openshaw, R., Thomson, D., Pratt, J., & Morris, B. (2015). P.1.h.022 Mice haploinsufficient for Map2k7, a schizophrenia risk gene, show impaired associative learning and attentional deficits: Impact of minocycline. Scientific Publication. https://www.semanticscholar.org/paper/411a77e8f805f3249f354fd86e0ce9d257c3b2ae

[10] Chen, T. J., Du, W., Junco, J. J., Bridges, C. S., Shen, Y., Puppi, M., Rabin, K., & Lacorazza, H. (2021). Inhibition of the MAP2K7-JNK pathway with 5Z-7-oxozeaenol induces apoptosis in T-cell acute lymphoblastic leukemia. OncoTarget. https://www.semanticscholar.org/paper/6c4379dbb120e6aa4b82f60f91c70b48028a885f

[11] Openshaw, R., Thomson, D., Thompson, R., Penninger, J., Pratt, J., Morris, B., & Dawson, N. (2019). Map2k7 Haploinsufficiency Induces Brain Imaging Endophenotypes and Behavioral Phenotypes Relevant to Schizophrenia. Schizophrenia Bulletin. https://www.semanticscholar.org/paper/69bf84a056248f2e09d7245cb8a2b1a46b2c6b29

[12] Shen, Y., Park, C., Suppipat, K., Mistretta, T.-A., Puppi, M., Horton, T., Rabin, K. R., Meijerink, J., & Lacorazza, H. D. (2016). Inactivation of KLF4 promotes T-cell acute lymphoblastic leukemia and activates the MAP2K7 pathway. Leukemia. https://www.semanticscholar.org/paper/7fa202c4fbc6eded9cfba7e6031ed3352efd871f

[13] Shen, Y., Park, C., Suppipat, K., Mistretta, T.-A., Puppi, M., Horton, T., Rabin, K., & Lacorazza, D. (2016). Abstract LB-181: KLF4 suppresses T-cell acute lymphoblastic leukemia by inhibiting the stress kinase MAP2K7 pathway. Scientific Publication. https://www.semanticscholar.org/paper/f67e